221 related articles for article (PubMed ID: 16203649)
1. Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms.
Ylikorkala O
Climacteric; 2005 Oct; 8 Suppl 3():1-3. PubMed ID: 16203649
[No Abstract] [Full Text] [Related]
2. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
3. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
Oelkers WH
Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
Sangthawan M; Taneepanichskul S
Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
[TBL] [Abstract][Full Text] [Related]
5. Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data.
Archer DF
J Reprod Med; 2007 Feb; 52(2 Suppl):159-64. PubMed ID: 17477110
[TBL] [Abstract][Full Text] [Related]
6. Effects of drospirenone/estrogen combinations on bone metabolism.
Christiansen C
Climacteric; 2005 Oct; 8 Suppl 3():35-41. PubMed ID: 16203654
[TBL] [Abstract][Full Text] [Related]
7. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
Foidart JM; Faustmann T
Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
[TBL] [Abstract][Full Text] [Related]
9. Clinical experiences with drospirenone: from reproductive to postmenopausal years.
Pérez-López FR
Maturitas; 2008 Jun; 60(2):78-91. PubMed ID: 18468818
[TBL] [Abstract][Full Text] [Related]
10. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.
Rübig A
Climacteric; 2003 Oct; 6 Suppl 3():49-54. PubMed ID: 15018248
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
[TBL] [Abstract][Full Text] [Related]
12. Evolution of progestins. Focus on the novel progestin drospirenone.
Thorneycroft IH
J Reprod Med; 2002 Nov; 47(11 Suppl):975-80. PubMed ID: 12497671
[TBL] [Abstract][Full Text] [Related]
13. Drospirenone: a novel progestin.
Rapkin AJ; Winer SA
Expert Opin Pharmacother; 2007 May; 8(7):989-99. PubMed ID: 17472544
[TBL] [Abstract][Full Text] [Related]
14. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
15. Drospirenone, a progestin with added value for hypertensive postmenopausal women.
Archer DF
Menopause; 2007; 14(3 Pt 1):352-4. PubMed ID: 17414576
[No Abstract] [Full Text] [Related]
16. Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
Fruzzetti F; Lazzarini V; Ricci C; Quirici B; Gambacciani M; Paoletti AM; Genazzani AR
Contraception; 2007 Sep; 76(3):190-4. PubMed ID: 17707715
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of different progestogens: the special case of drospirenone.
Sitruk-Ware R
Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Yasmin in premenstrual symptoms.
Taneepanichskul S; Jaisamrarn U; Phupong V
Arch Gynecol Obstet; 2007 Jun; 275(6):433-8. PubMed ID: 17111156
[TBL] [Abstract][Full Text] [Related]
19. Menopause and cardiovascular disease: the evidence.
Rosano GM; Vitale C; Marazzi G; Volterrani M
Climacteric; 2007 Feb; 10 Suppl 1():19-24. PubMed ID: 17364594
[TBL] [Abstract][Full Text] [Related]
20. Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study.
Paoletti AM; Cagnacci A; Di Carlo C; Orrù MM; Neri M; D'Alterio MN; Melis GB
Gynecol Endocrinol; 2015 May; 31(5):384-7. PubMed ID: 25703254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
